skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Management of insomnia in elderly patients using eszopiclone

Review

(1358) Views  (588) Full article downloads

Authors: Cynthia Kirkwood, Ericka Breden

Published Date August 2010 Volume 2010:2 Pages 151 - 158
DOI: http://dx.doi.org/10.2147/NSS.S5133

Cynthia Kirkwood1, Ericka Breden2

1Department of Pharmacotherapy and Outcomes Science, 2Department of Pharmacy, Virginia Commonwealth University, Richmond, Virginia USA

Abstract: Insomnia is a common sleep complaint in the elderly. The safety and efficacy of eszopiclone, a non-benzodiazepine hypnotic, in elderly patients with chronic insomnia has been established in two 2-week and one 12-week randomized, double-blind, placebo-controlled ­trials. Eszopiclone 1 mg was effective in reducing sleep latency. Eszopiclone 2 mg was effective in reducing latency to sleep and for increasing sleep maintenance. Eszopiclone doses of 1 mg and 2 mg reduced the number of daytime naps and decreased the duration of naps in elderly patients. Eszopiclone 2 mg improved the quality of life measures for mood, physical health, household activities, medication, leisure activities, and self-report of physical functioning and vitality in the 2-week trials, and vitality and general health in the 12-week trial. The most commonly reported side effects in the elderly included unpleasant taste, dry mouth, dizziness, and somnolence. The concurrent use of drugs that inhibit or induce the cytochrome P450 enzyme CYP3A4 can alter concentrations of eszopiclone and the dose may need to be adjusted. The recommended starting dose of eszopiclone for difficulty falling asleep is 1 mg at bedtime. For elders who complain of difficulty maintaining sleep, eszopiclone should be initiated at 2 mg at bedtime. Overall, eszopiclone is a safe and well-tolerated treatment option for elderly patients with insomnia.

Keywords: eszopiclone, insomnia, elderly







Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
The association between insomnia and cardiovascular diseases
Management of insomnia: update and new approaches
Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression
Obstructive sleep apnea syndrome: natural history, diagnosis, and emerging treatment options
Pharmacotherapy for treatment-resistant schizophrenia
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio